Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 106.85%.

  • Ultragenyx Pharmaceutical's EBITDA Margin fell 122300.0% to 106.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.27%, marking a year-over-year increase of 162200.0%. This contributed to the annual value of 95.67% for FY2024, which is 354100.0% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its EBITDA Margin stood at 106.85% for Q3 2025, which was down 122300.0% from 64.8% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's EBITDA Margin's 5-year high stood at 64.8% during Q2 2025, with a 5-year trough of 248.14% in Q3 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median EBITDA Margin value was 110.02% (recorded in 2021), while the average stood at 124.3%.
  • In the last 5 years, Ultragenyx Pharmaceutical's EBITDA Margin surged by 2251100bps in 2021 and then crashed by -1381200bps in 2022.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EBITDA Margin stood at 122.99% in 2021, then dropped by -15bps to 140.91% in 2022, then surged by 32bps to 95.81% in 2023, then rose by 23bps to 74.16% in 2024, then tumbled by -44bps to 106.85% in 2025.
  • Its EBITDA Margin was 106.85% in Q3 2025, compared to 64.8% in Q2 2025 and 102.62% in Q1 2025.